» Articles » PMID: 28205671

Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis

Overview
Journal Clin Infect Dis
Date 2017 Feb 17
PMID 28205671
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There is scant evidence to support target drug exposures for optimal tuberculosis outcomes. We therefore assessed whether pharmacokinetic/pharmacodynamic (PK/PD) parameters could predict 2-month culture conversion.

Methods: One hundred patients with pulmonary tuberculosis (65% human immunodeficiency virus coinfected) were intensively sampled to determine rifampicin, isoniazid, and pyrazinamide plasma concentrations after 7-8 weeks of therapy, and PK parameters determined using nonlinear mixed-effects models. Detailed clinical data and sputum for culture were collected at baseline, 2 months, and 5-6 months. Minimum inhibitory concentrations (MICs) were determined on baseline isolates. Multivariate logistic regression and the assumption-free multivariate adaptive regression splines (MARS) were used to identify clinical and PK/PD predictors of 2-month culture conversion. Potential PK/PD predictors included 0- to 24-hour area under the curve (AUC0-24), maximum concentration (Cmax), AUC0-24/MIC, Cmax/MIC, and percentage of time that concentrations persisted above the MIC (%TMIC).

Results: Twenty-six percent of patients had Cmax of rifampicin <8 mg/L, pyrazinamide <35 mg/L, and isoniazid <3 mg/L. No relationship was found between PK exposures and 2-month culture conversion using multivariate logistic regression after adjusting for MIC. However, MARS identified negative interactions between isoniazid Cmax and rifampicin Cmax/MIC ratio on 2-month culture conversion. If isoniazid Cmax was <4.6 mg/L and rifampicin Cmax/MIC <28, the isoniazid concentration had an antagonistic effect on culture conversion. For patients with isoniazid Cmax >4.6 mg/L, higher isoniazid exposures were associated with improved rates of culture conversion.

Conclusions: PK/PD analyses using MARS identified isoniazid Cmax and rifampicin Cmax/MIC thresholds below which there is concentration-dependent antagonism that reduces 2-month sputum culture conversion.

Citing Articles

A Nanopore Sequencing-based Pharmacogenomic Panel to Personalize Tuberculosis Drug Dosing.

Verma R, Da Silva K, Rockwood N, Wasmann R, Yende N, Song T Am J Respir Crit Care Med. 2024; 209(12):1486-1496.

PMID: 38647526 PMC: 11208962. DOI: 10.1164/rccm.202309-1583OC.


Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of rifampicin- or multidrug-resistant tuberculosis in Indonesia.

Yunivita V, Gafar F, Santoso P, Chaidir L, Soeroto A, Meirina T J Antimicrob Chemother. 2024; 79(5):977-986.

PMID: 38459759 PMC: 11062943. DOI: 10.1093/jac/dkae057.


Is the Pharmacokinetics of First-Line Anti-TB Drugs a Cause of High Mortality Rates in TB Patients Admitted to the ICU? A Non-Compartmental Pharmacokinetic Analysis.

Beraldi-Magalhaes F, Parker S, Sanches C, Garcia L, Souza Carvalho B, Costa A Trop Med Infect Dis. 2023; 8(6).

PMID: 37368730 PMC: 10303681. DOI: 10.3390/tropicalmed8060312.


Determining the Delamanid Pharmacokinetics/Pharmacodynamics Susceptibility Breakpoint Using Monte Carlo Experiments.

Liu Y, Moodley M, Pasipanodya J, Gumbo T Antimicrob Agents Chemother. 2023; 67(4):e0140122.

PMID: 36877034 PMC: 10112185. DOI: 10.1128/aac.01401-22.


Intensified Antituberculosis Therapy Regimen Containing Higher Dose Rifampin for Tuberculous Meningitis: A Systematic Review and Meta-Analysis.

Zhang M, Wang M, He J Front Med (Lausanne). 2022; 9:822201.

PMID: 35280900 PMC: 8916538. DOI: 10.3389/fmed.2022.822201.


References
1.
Alsultan A, Peloquin C . Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014; 74(8):839-54. DOI: 10.1007/s40265-014-0222-8. View

2.
Chideya S, Winston C, Peloquin C, Bradford W, Hopewell P, Wells C . Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis. 2009; 48(12):1685-94. PMC: 3762461. DOI: 10.1086/599040. View

3.
Jayaram R, Gaonkar S, Kaur P, Suresh B, Mahesh B, Jayashree R . Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother. 2003; 47(7):2118-24. PMC: 161844. DOI: 10.1128/AAC.47.7.2118-2124.2003. View

4.
Grosset J, Almeida D, Converse P, Tyagi S, Li S, Ammerman N . Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide. Proc Natl Acad Sci U S A. 2012; 109(37):15001-5. PMC: 3443175. DOI: 10.1073/pnas.1203636109. View

5.
Phillips P, Fielding K, Nunn A . An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse. PLoS One. 2013; 8(5):e63840. PMC: 3648512. DOI: 10.1371/journal.pone.0063840. View